West Nile virus (WNV) is a member of the family Flaviviridae, which also includes the St Louis encephalitis, the Japanese encephalitis, and the hepatitis C viruses. The natural reservoir of the virus is wild birds and it is transmitted by mosquitoes to humans, horses, and other domestic animals, which are incidental hosts. Until recently West Nile fever (WNF) was considered a benign illness with most human infections being asymptomatic. When clinically apparent, WNF is usually mild in children and young adults, but tends to be more severe in the elderly. The most frequent manifestations of WNV infection are fever, headache, myalgia, diffuse lymphadenopathy, and non-pruritic maculopapular rash which occurs in about 50% of patients. Neurological manifestations are uncommon and range from mild aseptic meningitis to severe encephalitis (which is extremely rare in children).

In Israel WNV is endemic. Several outbreaks of WNF have occurred in the past, the last one being in 1981. An outbreak of WNF took place in Israel between August and October 2000. The vectors of WNV were mosquitoes of the Culex species; the reservoir was wild birds (pigeons, storks, and crows). A total of 417 people were serologically confirmed to have the disease, with 60% polymorphonuclear cells and 40% lymphocytes, protein was 109 mg/dl, and glucose 55 mg/dl (85 mg/dl in serum). No malignant cells were found and the CSF bacterial culture was sterile. Polymerase chain reaction (PCR) for herpes simplex DNA was also negative. Serologies for mycoplasma, Epstein–Barr virus (EBV), and cytomegalovirus were negative. An electroencephalogram revealed generalised slow waves in the delta range compatible with severe encephalitis. A brain computed tomography scan was normal. With the presumptive diagnosis of meningoencephalitis, antimicrobial treatment was changed to intravenous ceftriaxone 100 mg/kg/day, intravenous vancomycin 40 mg/kg/day, and intravenous aciclovir 30 mg/kg/day until microbiology and PCR virology results became available. The WBC and ANC continued to decline in parallel to neurological deterioration, reaching their nadir on the sixth hospital day (WBC 1070/mm$^3$ and ANC 310/mm$^3$). Despite aggressive treatment with mannitol and anticonvulsive medications, the neurological abnormalities progressed. He developed motor aphasia, became completely bedridden, and required nasogastric feeding. His Glasgow coma scale was 7 of 15, yet there was no need to ventilate him and he remained haemodynamically stable. At this stage the results of serum IgM specific antibodies to WNV obtained on the fourth day after admission, were reported to be positive. On the eighth day after admission, ribavirin 200 mg four times daily had been given via nasogastric tube for 14 days. Repeated blood counts showed no evidence of haemolysis as a complication of the ribavirin treatment; there was a gradual increase in both WBC count and ANC, reaching normal values on the 12th day after admission.

Slow improvement in neurological state was noted at the beginning of the third week. With the help of intensive auxiliary and supportive care (physical and occupational therapy) he recovered completely after four months.
his neurological deficits gradually disappeared, and he was discharged 28 days after admission. The motor aphasia was the last to resolve, lasting more than three months. At follow up, eight months after discharge, he had achieved complete neurological recovery and had completed the course of chemotherapy.

DISCUSSION
In the past decade, several epidemics of WNF have occurred throughout the world, including the Czech Republic,7 Romania,8 Russia,9 and the United States.10–13 The 1999 outbreak in New York was the first reported WNF outbreak in the Western hemisphere.14 These reports changed the general conception of WNF being a mild febrile illness with limited CNS involvement and very low mortality rate. In the Romanian, Russian, and New Yorks epidemics a high percentage of CNS involvement was reported, as well as high mortality rates (4.3%, 4.0 %, and 11.5%, respectively).7–13

The Israeli 2000 outbreak was characterised by a country-wide spread, high percentage of neurological involvement (73% of hospitalised patients), especially in the elderly, and a high case fatality rate.7 Even in these epidemics, however, severe neurological morbidity did not occur in children. Of the 24 children diagnosed with WNF during the 2000 outbreak in Israel, all but one had mild disease. Most had aseptic meningitis. Our patient had the most severe course in the infected paediatric population, probably a result of his immunodeficiency state.

The most common CNS manifestations of WNV are aseptic meningitis, encephalitis, myelitis, radiculopathy (a Guillain-Barré like syndrome), and peripheral neuropathy.7–10 12 15 To our knowledge, motor aphasia as a complication of WNV encephalitis has not been reported. It seems that the severe manifestation in our patient occurred in part because of his immunodeficiency.

The complete recovery of our patient took place in conjunction with the increase in WBC and ANC (host immunity), both to the normal range, and initiation of ribavirin treatment. Ribavirin is a synthetic guanosine analogue that inhibits replication of DNA and RNA viruses.16 Ribavirin and interferon alfa 2b are very active against hepatitis C virus, which belongs to the Flaviviridae family, to which WNV also belongs.17 18 A recent in vitro study showed the inhibitory effect of ribavirin on WNV replication and on its cytopathic effect in neural cells.19 This suggests that ribavirin could be effective in patients with WNV infection.

A multicentre clinical trial of ribavirin in WNF patients was initiated in the Israeli 2000 outbreak (unpublished data). Although our patient was not included in this trial (inclusion criteria >17 years), we decided to treat him with this agent in view of his progressing neurological deterioration and failure of the previous therapy. We assume that the combination of recovered host immunity and antiviral medication resulted in his gradual later improvement.

In summary, immunodeficiency places children at increased risk for severe WNV neurological disease. Early diagnosis and restoration of host immunity are crucial. Ribavirin, an experimental treatment for this infection, should be considered if spontaneous improvement does not occur.

Authors’ affiliations
R Spiegel, Y Horovitz, Pediatric Department A’, Ha’Emek Medical Center, Afula, Rappaport School of Medicine, Technion, Haifa, Israel
D Miron, Pediatric Infectious Disease Division, Ha’Emek Medical Center
H Gavriel, Pediatric Hematology-Oncology Department, Ha’Emek Medical Center

Correspondence to: Dr R Spiegel, Department of Pediatrics A, Ha’Emek Medical Center, Afula 18101, Israel; spiegelr@internet-zahav.net

Accepted 25 February 2002

REFERENCES
West Nile virus meningoencephalitis complicated by motor aphasia in Hodgkin's lymphoma

R Spiegel, D Miron, H Gavriel and Y Horovitz

*Arch Dis Child* 2002 86: 441-442
doi: 10.1136/adc.86.6.441

Updated information and services can be found at:
http://adc.bmj.com/content/86/6/441

These include:

**References**

This article cites 15 articles, 2 of which you can access for free at:
http://adc.bmj.com/content/86/6/441#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Infection (neurology) (287)
- Meningitis (197)
- Oncology (777)
- Drugs: infectious diseases (965)
- Epilepsy and seizures (391)
- Immunology (including allergy) (2018)
- Child health (3922)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/